ShockWave Medical (SWAV) Stock Forecast, Price Target & Predictions
SWAV Stock Forecast
ShockWave Medical stock forecast is as follows: an average price target of $258.17 (represents a -22.88% downside from SWAV’s last price of $334.75) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
SWAV Price Target
The average price target for ShockWave Medical (SWAV) is $258.17 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $360.00 to $175.00. This represents a potential -22.88% downside from SWAV's last price of $334.75.
SWAV Analyst Ratings
According to 10 Wall Street analysts, ShockWave Medical's rating consensus is 'Hold'. The analyst rating breakdown for SWAV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (10.00%), 8 'Hold' (80.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).
ShockWave Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 05, 2024 | William Plovanic | Johnson Rice | $335.00 | $325.48 | 2.92% | 0.07% |
| Apr 02, 2024 | Adam Maeder | Piper Sandler | $360.00 | $320.51 | 12.32% | 7.54% |
| Jan 06, 2023 | - | Morgan Stanley | $224.00 | $208.17 | 7.60% | -33.08% |
| Aug 29, 2022 | - | Piper Sandler | $338.00 | $304.44 | 11.02% | 0.97% |
| Aug 09, 2022 | - | Morgan Stanley | $255.00 | $258.93 | -1.52% | -23.82% |
| Aug 09, 2022 | - | Wells Fargo | $255.00 | $221.77 | 14.98% | -23.82% |
| Aug 09, 2022 | - | Piper Sandler | $278.00 | $221.77 | 25.36% | -16.95% |
| Jul 15, 2022 | - | Morgan Stanley | $201.00 | $209.90 | -4.24% | -39.96% |
| May 10, 2022 | - | Morgan Stanley | $180.00 | $133.39 | 34.94% | -46.23% |
| May 10, 2022 | - | Wells Fargo | $176.00 | $115.91 | 51.84% | -47.42% |
The latest ShockWave Medical stock forecast, released on Apr 05, 2024 by William Plovanic from Johnson Rice, set a price target of $335.00, which represents a 2.92% increase from the stock price at the time of the forecast ($325.48), and a 0.07% increase from SWAV last price ($334.75).
ShockWave Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $347.50 |
| Last Closing Price | $334.75 | $334.75 | $334.75 |
| Upside/Downside | -100.00% | -100.00% | 3.81% |
In the current month, the average price target of ShockWave Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ShockWave Medical's last price of $334.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 09, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 08, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Apr 08, 2024 | Johnson Rice | Market Perform | Neutral | Downgrade |
| Apr 05, 2024 | Johnson Rice | Hold | Market Perform | Downgrade |
| Apr 05, 2024 | Johnson Rice | - | Hold | Downgrade |
| Apr 05, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Apr 05, 2024 | Needham | Buy | Hold | Downgrade |
| Apr 04, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
| Mar 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 24, 2023 | Needham | Buy | Buy | Hold |
ShockWave Medical's last stock rating was published by Wells Fargo on May 09, 2024. The company gave SWAV a "Equal-Weight" rating, the same as its previous rate.
ShockWave Medical Financial Forecast
ShockWave Medical Revenue Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $202.98M | - | - | $161.07M | $144.03M | - | - | $93.63M | $84.18M | $65.16M | $55.91M | $31.90M | $22.72M | $19.59M | $10.29M | $15.20M | $14.31M | $11.33M |
| Avg Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $227.06M | $207.67M | $199.43M | $184.72M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $86.41M | $75.43M | $61.21M | $45.22M | $29.90M | $20.16M | $14.68M | $8.35M | $14.17M | $13.47M | $10.43M |
| High Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $230.18M | $207.67M | $200.00M | $187.99M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $87.68M | $76.54M | $62.11M | $45.88M | $30.34M | $20.45M | $14.89M | $8.47M | $14.38M | $13.67M | $10.58M |
| Low Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $225.28M | $207.67M | $199.10M | $182.70M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $85.33M | $74.49M | $60.44M | $44.65M | $29.53M | $19.91M | $14.49M | $8.24M | $14.00M | $13.31M | $10.30M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | - | - | 1.09% | 1.01% | - | - | 1.08% | 1.12% | 1.06% | 1.24% | 1.07% | 1.13% | 1.33% | 1.23% | 1.07% | 1.06% | 1.09% |
ShockWave Medical's average Quarter revenue forecast for Mar 24 based on 3 analysts is $207.67M, with a low forecast of $207.67M, and a high forecast of $207.67M. SWAV's average Quarter revenue forecast represents a 2.31% increase compared to the company's last Quarter revenue of $202.98M (Dec 23).
ShockWave Medical EBITDA Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $46.36M | - | - | $41.37M | $45.62M | - | - | $16.73M | $15.02M | $3.67M | $1.23M | $-22.12M | $-296.87K | $-11.73M | $-16.98M | $-17.68M | $-13.85M | $-12.10M |
| Avg Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-67.70M | $18.68M | $-59.46M | $-55.07M | $-51.83M | $16.98M | $-42.69M | $10.30M | $-32.05M | $15.44M | $38.61M | $9.36M | $2.18M | $-11.90M | $-268.60K | $-15.36M | $-18.62M | $-14.07M | $-14.39M | $-13.29M |
| High Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-67.17M | $22.42M | $-59.36M | $-54.47M | $-51.83M | $20.38M | $-42.69M | $12.36M | $-32.05M | $18.53M | $46.34M | $11.24M | $2.62M | $-9.52M | $-214.88K | $-12.29M | $-14.89M | $-11.26M | $-11.51M | $-10.63M |
| Low Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-68.62M | $14.94M | $-59.63M | $-56.05M | $-51.83M | $13.59M | $-42.69M | $8.24M | $-32.05M | $12.35M | $30.89M | $7.49M | $1.75M | $-14.27M | $-322.32K | $-18.43M | $-22.34M | $-16.89M | $-17.27M | $-15.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.78% | - | - | 2.44% | -1.07% | - | - | 1.08% | 0.39% | 0.39% | 0.56% | 1.86% | 1.11% | 0.76% | 0.91% | 1.26% | 0.96% | 0.91% |
3 analysts predict SWAV's average Quarter EBITDA for Mar 24 to be $18.68M, with a high of $22.42M and a low of $14.94M. This is -59.70% lower than ShockWave Medical's previous annual EBITDA (Dec 23) of $46.36M.
ShockWave Medical Net Income Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $44.30M | - | - | $39.13M | $140.91M | - | - | $14.52M | $12.94M | $1.95M | $-425.00K | $-23.60M | $-15.87K | $-12.93M | $-18.12M | $-18.77M | $-14.74M | $-12.96M |
| Avg Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $45.16M | $16.21M | $34.25M | $29.98M | $31.87M | $14.74M | $38.80M | $5.46M | $17.06M | $13.40M | $33.28M | $4.97M | $-755.67K | $-12.69M | $-14.36K | $-16.93M | $-19.87M | $-14.94M | $-15.32M | $-14.23M |
| High Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $55.07M | $19.45M | $43.55M | $36.81M | $31.87M | $17.68M | $38.80M | $6.56M | $17.06M | $16.08M | $39.94M | $5.96M | $-604.54K | $-10.15M | $-11.49K | $-13.54M | $-15.90M | $-11.95M | $-12.26M | $-11.38M |
| Low Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $42.59M | $12.97M | $30.90M | $24.29M | $31.87M | $11.79M | $38.80M | $4.37M | $17.06M | $10.72M | $26.62M | $3.97M | $-906.80K | $-15.23M | $-17.23K | $-20.31M | $-23.85M | $-17.93M | $-18.39M | $-17.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.29% | - | - | 2.66% | 3.63% | - | - | 1.08% | 0.39% | 0.39% | 0.56% | 1.86% | 1.11% | 0.76% | 0.91% | 1.26% | 0.96% | 0.91% |
ShockWave Medical's average Quarter net income forecast for Mar 24 is $16.21M, with a range of $12.97M to $19.45M. SWAV's average Quarter net income forecast represents a -63.41% decrease compared to the company's last Quarter net income of $44.30M (Dec 23).
ShockWave Medical SG&A Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $92.06M | - | - | $73.22M | $60.38M | - | - | $48.35M | $42.82M | $37.66M | $34.34M | $31.22M | $23.07M | $19.23M | $16.60M | $16.64M | $14.05M | $11.63M |
| Avg Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $166.31M | $53.97M | $146.07M | $135.29M | $127.33M | $49.07M | $104.87M | $105.63M | $78.75M | $44.61M | $55.25M | $44.83M | $33.12M | $16.79M | $14.76M | $10.75M | $6.11M | $13.24M | $9.87M | $7.64M |
| High Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $168.60M | $64.77M | $146.49M | $137.70M | $127.33M | $58.88M | $104.87M | $126.76M | $78.75M | $53.53M | $56.06M | $45.49M | $33.61M | $20.15M | $14.98M | $10.91M | $6.20M | $15.89M | $10.01M | $7.75M |
| Low Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $165.01M | $43.18M | $145.83M | $133.82M | $127.33M | $39.25M | $104.87M | $84.50M | $78.75M | $35.68M | $54.56M | $44.27M | $32.70M | $13.43M | $14.58M | $10.62M | $6.04M | $10.59M | $9.75M | $7.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% | - | - | 1.49% | 0.58% | - | - | 1.08% | 0.78% | 0.84% | 1.04% | 1.86% | 1.56% | 1.79% | 2.72% | 1.26% | 1.42% | 1.52% |
ShockWave Medical's average Quarter SG&A projection for Mar 24 is $53.97M, based on 3 Wall Street analysts, with a range of $43.18M to $64.77M. The forecast indicates a -41.37% fall compared to SWAV last annual SG&A of $92.06M (Dec 23).
ShockWave Medical EPS Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.16 | - | - | $1.07 | $3.89 | - | - | $0.41 | $0.37 | $0.06 | $-0.01 | $-0.68 | $-0.00 | $-0.38 | $-0.56 | $-0.59 | $-0.49 | $-0.46 |
| Avg Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.17 | $0.99 | $0.89 | $0.78 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.18 | $0.09 | $-0.06 | $-0.40 | $-0.45 | $-0.42 | $-0.55 | $-0.62 | $-0.49 | $-0.51 | $-0.51 |
| High Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.43 | $0.99 | $1.13 | $0.96 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.19 | $0.09 | $-0.06 | $-0.39 | $-0.44 | $-0.42 | $-0.54 | $-0.61 | $-0.48 | $-0.50 | $-0.50 |
| Low Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.11 | $0.99 | $0.80 | $0.63 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.18 | $0.08 | $-0.06 | $-0.41 | $-0.45 | $-0.43 | $-0.56 | $-0.63 | $-0.50 | $-0.52 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% | - | - | 1.35% | 3.86% | - | - | 2.23% | 4.34% | -1.06% | 0.03% | 1.52% | 0.00% | 0.69% | 0.90% | 1.20% | 0.96% | 0.90% |
According to 3 Wall Street analysts, ShockWave Medical's projected average Quarter EPS for Mar 24 is $0.99, with a low estimate of $0.99 and a high estimate of $0.99. This represents a -14.72% decrease compared to SWAV previous annual EPS of $1.16 (Dec 23).
ShockWave Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OM | Outset Medical | $0.53 | $11.00 | 1975.47% | Buy |
| ALGN | Align | $243.73 | $554.38 | 127.46% | Buy |
| TNDM | Tandem Diabetes Care | $43.97 | $84.44 | 92.04% | Buy |
| NARI | Inari Medical | $46.52 | $72.88 | 56.66% | Buy |
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| MASI | Masimo | $112.80 | $158.40 | 40.43% | Buy |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| PEN | Penumbra | $186.94 | $218.89 | 17.09% | Hold |
| INSP | Inspire Medical Systems | $203.99 | $237.80 | 16.57% | Buy |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| TMDX | TransMedics Group | $151.42 | $156.86 | 3.59% | Buy |
| CLPT | ClearPoint Neuro | $12.59 | $12.00 | -4.69% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
SWAV Forecast FAQ
Is ShockWave Medical a good buy?
No, according to 10 Wall Street analysts, ShockWave Medical (SWAV) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 10.00% of SWAV's total ratings.
What is SWAV's price target?
ShockWave Medical (SWAV) average price target is $258.17 with a range of $175 to $360, implying a -22.88% from its last price of $334.75. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ShockWave Medical stock go up soon?
According to Wall Street analysts' prediction for SWAV stock, the company can go down by -22.88% (from the last price of $334.75 to the average price target of $258.17), up by 7.54% based on the highest stock price target, and down by -47.72% based on the lowest stock price target.
Can ShockWave Medical stock reach $500?
SWAV's average twelve months analyst stock price target of $258.17 does not support the claim that ShockWave Medical can reach $500 in the near future.
What are ShockWave Medical's analysts' financial forecasts?
ShockWave Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.14B (high $1.14B, low $1.14B), average EBITDA is $-338M (high $-338M, low $-338M), average net income is $244.88M (high $244.88M, low $244.88M), average SG&A $831.44M (high $831.44M, low $831.44M), and average EPS is $6.37 (high $6.37, low $6.37). SWAV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.33B (high $1.33B, low $1.33B), average EBITDA is $-398M (high $-398M, low $-398M), average net income is $281.41M (high $281.41M, low $281.41M), average SG&A $976.98M (high $976.98M, low $976.98M), and average EPS is $7.31 (high $7.31, low $7.31).
Did the SWAV's actual financial results beat the analysts' financial forecasts?
Based on ShockWave Medical's last annual report (Dec 2023), the company's revenue was $730.23M, beating the average analysts forecast of $705.28M by 3.54%. Apple's EBITDA was $169.45M, missing the average prediction of $-149M by -213.44%. The company's net income was $147.28M, beating the average estimation of $110.83M by 32.88%. Apple's SG&A was $330.1M, missing the average forecast of $457.76M by -27.89%. Lastly, the company's EPS was $3.85, beating the average prediction of $3.29 by 16.95%. In terms of the last quarterly report (Dec 2023), ShockWave Medical's revenue was $202.98M, beating the average analysts' forecast of $199.43M by 1.78%. The company's EBITDA was $46.36M, missing the average prediction of $-59.457M by -177.97%. ShockWave Medical's net income was $44.3M, beating the average estimation of $34.25M by 29.37%. The company's SG&A was $92.06M, missing the average forecast of $146.07M by -36.98%. Lastly, the company's EPS was $1.16, beating the average prediction of $0.89 by 30.31%